Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 8/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736320 | 0.84 | EGFR (0.57) | KHKEGFRERBB2 | |
| SCHEMBL1105370 | 0.84 | EGFR (0.57) | KHKEGFRERBB2 | |
| SCHEMBL4734673 | 0.83 | EGFR (0.48) | EGFRERBB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1096423 | 0.78 | EGFR (0.54) | EGFRERBB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4734704 | 0.77 | EGFR (0.58) | EGFRERBB2 | |
| SCHEMBL1095082 | 0.77 | EGFR (0.47) | EGFRTRPV1ERBB2ALDH1A1 | |
| SCHEMBL1094892 | 0.76 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL1096401 | 0.75 | ABCG2 (0.55) | EGFRTNNI3KERBB2SMN1; SMN2 | |
| SCHEMBL1095423 | 0.74 | EGFR (0.59) | EGFRERBB2ALDH1A1 | |
| SCHEMBL1095176 | 0.74 | EGFR (0.50) | EGFRTNNI3KERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | claimed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | claimed |
| WO-2007081630-A2 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | claimed |
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | disclosed |
| WO-2007081630-A2 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | KHK 495/4885EGFR 1201/4885TRPV1 4427/4885 |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | KHK 495/4885EGFR 1201/4885TRPV1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.